PE20211456A1 - 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND ITS DERIVATIVES FOR THE TREATMENT AND PREVENTION OF LIVER CANCER - Google Patents
7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND ITS DERIVATIVES FOR THE TREATMENT AND PREVENTION OF LIVER CANCERInfo
- Publication number
- PE20211456A1 PE20211456A1 PE2020001228A PE2020001228A PE20211456A1 PE 20211456 A1 PE20211456 A1 PE 20211456A1 PE 2020001228 A PE2020001228 A PE 2020001228A PE 2020001228 A PE2020001228 A PE 2020001228A PE 20211456 A1 PE20211456 A1 PE 20211456A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- prevention
- derivatives
- treatment
- substituted
- Prior art date
Links
- -1 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS Chemical class 0.000 title abstract 3
- 201000007270 liver cancer Diseases 0.000 title abstract 2
- 208000014018 liver neoplasm Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- WKHUVUVRZWSZKX-UHFFFAOYSA-N 6-amino-9-benzyl-N-methyl-8-oxo-N-propyl-2-(propylsulfonimidoyl)purine-7-carboxamide Chemical compound NC1=C2N(C(N(C2=NC(=N1)S(=O)(=N)CCC)CC1=CC=CC=C1)=O)C(=O)N(CCC)C WKHUVUVRZWSZKX-UHFFFAOYSA-N 0.000 abstract 1
- 229940124060 PD-1 antagonist Drugs 0.000 abstract 1
- 229940123751 PD-L1 antagonist Drugs 0.000 abstract 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referido a un compuesto de formula I, en donde R1 es alquilo-C1-6; R2 es bencilo, en donde no esta sustituido o esta sustituido con uno, dos o tres sustituyentes seleccionados independientemente de halogeno y alquilo-C1-6; R3 es -NR4R5, en donde R4 es alquilo-C1-6 o alcoxi-C1-6-alquilo-C1-6; R5 es (alquil-C1-6)2NCOO-alquilo-C1-6, alcoxi-C1-6- alquilo-C1-6, entre otros; o una sal farmaceuticamente aceptable, enantiomero o diastereomero del mismo. Un compuesto seleccionado es 6-amino-9-bencil-N-metil-8-oxo-N-propil-2-(propilsulfonimidoil)purin-7-carboxamida. Estos compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados tienen actividad agonista del receptor tipo Toll (TLR) in vivo, son utilizados en el tratamiento y prevencion del cancer de higado. Tambien se refiere a compuestos intermedios, preparacion de los mismos, composicion farmaceutica que comprende dicho compuesto en combinacion con un anticuerpo antagonista de PD1 o un anticuerpo antagonista de PD-L1.Referred to a compound of formula I, wherein R1 is C1-6 alkyl; R2 is benzyl, where it is unsubstituted or substituted with one, two, or three substituents independently selected from halogen and C1-6alkyl; R3 is -NR4R5, wherein R4 is -C 1-6 alkyl or -C 1-6 alkoxy-C1-6 alkyl; R5 is (C1-6 alkyl) 2NCOO-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, among others; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. A selected compound is 6-amino-9-benzyl-N-methyl-8-oxo-N-propyl-2- (propylsulfonimidoyl) purine-7-carboxamide. These 7-substituted sulfonimidoylpurinone compounds and their derivatives have Toll-like receptor (TLR) agonist activity in vivo, they are used in the treatment and prevention of liver cancer. It also refers to intermediates, preparation thereof, pharmaceutical composition comprising said compound in combination with a PD1 antagonist antibody or a PD-L1 antagonist antibody.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018077501 | 2018-02-28 | ||
| PCT/EP2019/054729 WO2019166432A1 (en) | 2018-02-28 | 2019-02-26 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211456A1 true PE20211456A1 (en) | 2021-08-05 |
Family
ID=65685310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001228A PE20211456A1 (en) | 2018-02-28 | 2019-02-26 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND ITS DERIVATIVES FOR THE TREATMENT AND PREVENTION OF LIVER CANCER |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3758707A1 (en) |
| JP (1) | JP7089596B2 (en) |
| KR (1) | KR20200128414A (en) |
| CN (1) | CN111801100B (en) |
| AR (1) | AR114419A1 (en) |
| AU (1) | AU2019228654A1 (en) |
| BR (1) | BR112020016509A2 (en) |
| CA (1) | CA3091950A1 (en) |
| CL (1) | CL2020002139A1 (en) |
| CO (1) | CO2020010306A2 (en) |
| IL (1) | IL276817A (en) |
| MA (1) | MA52412A (en) |
| MX (1) | MX2020008746A (en) |
| PE (1) | PE20211456A1 (en) |
| PH (1) | PH12020551343A1 (en) |
| RU (1) | RU2020131012A (en) |
| SG (1) | SG11202008291XA (en) |
| TW (1) | TW202003518A (en) |
| WO (1) | WO2019166432A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| CR20200372A (en) | 2018-02-28 | 2020-10-26 | Novartis Ag | DERIVATIVES OF 10- (DI (PHENYL) METHYL) -4-HYDROXY8,9,9A, 10-TETRAHYDRO-7H-PYRROLE (1`, 2`: 4-5) PIRAZINE (1,2-B) PYRIDAZINE-3, 5-DIONA AND RELATED COMPOUNDS AS INHIBITORS OF THE REPLICATION OF ORTHOMYX VIRUS FOR THE TREATMENT OF INFLUENZA |
| KR102409595B1 (en) | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | Novel purinone derivatives as protein kinase CSF-1R inhibitor |
| CN112420196A (en) * | 2020-11-20 | 2021-02-26 | 长沙市弘源心血管健康研究院 | Prediction method and system for survival rate of acute myocardial infarction patient within 5 years |
| JP2025522978A (en) * | 2022-07-14 | 2025-07-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Phosphorylpurinone compounds for the treatment of cancer - Patents.com |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (en) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | Heterocyclic compounds |
| SG172060A1 (en) | 2008-12-09 | 2011-07-28 | Gilead Sciences Inc | Modulators of toll-like receptors |
| MX2011012337A (en) * | 2009-05-21 | 2011-12-08 | Dainippon Sumitomo Pharma Co | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases. |
| CN102666541B (en) * | 2009-10-22 | 2015-11-25 | 吉里德科学公司 | Derivatives of purines or deazapurines for use in the treatment, especially of viral infections |
| WO2011079016A1 (en) * | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| US8592427B2 (en) * | 2010-06-24 | 2013-11-26 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| US20120039916A1 (en) * | 2010-08-13 | 2012-02-16 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| UA120450C2 (en) * | 2015-05-08 | 2019-12-10 | Ф. Хоффманн-Ля Рош Аг | SULPHONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR TREATMENT AND PREVENTION OF VIRAL INFECTION |
| MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
| KR102459155B1 (en) * | 2016-08-29 | 2022-10-28 | 에프. 호프만-라 로슈 아게 | 7-Substituted Sulfonimidoylpurinone Compounds for Treatment and Prevention of Viral Infections |
| BR112019004560A2 (en) * | 2016-09-13 | 2019-07-02 | Hoffmann La Roche | combination treatment with tlr7 agonist and a hbv capsid formation inhibitor |
-
2019
- 2019-02-26 JP JP2020544794A patent/JP7089596B2/en active Active
- 2019-02-26 CA CA3091950A patent/CA3091950A1/en active Pending
- 2019-02-26 WO PCT/EP2019/054729 patent/WO2019166432A1/en not_active Ceased
- 2019-02-26 SG SG11202008291XA patent/SG11202008291XA/en unknown
- 2019-02-26 PE PE2020001228A patent/PE20211456A1/en unknown
- 2019-02-26 EP EP19708981.6A patent/EP3758707A1/en not_active Withdrawn
- 2019-02-26 KR KR1020207027935A patent/KR20200128414A/en not_active Ceased
- 2019-02-26 RU RU2020131012A patent/RU2020131012A/en unknown
- 2019-02-26 CN CN201980015912.7A patent/CN111801100B/en active Active
- 2019-02-26 BR BR112020016509-3A patent/BR112020016509A2/en not_active Application Discontinuation
- 2019-02-26 MA MA052412A patent/MA52412A/en unknown
- 2019-02-26 MX MX2020008746A patent/MX2020008746A/en unknown
- 2019-02-26 AU AU2019228654A patent/AU2019228654A1/en not_active Abandoned
- 2019-02-27 TW TW108106752A patent/TW202003518A/en unknown
- 2019-02-28 AR ARP190100505A patent/AR114419A1/en unknown
-
2020
- 2020-08-19 CL CL2020002139A patent/CL2020002139A1/en unknown
- 2020-08-19 IL IL276817A patent/IL276817A/en unknown
- 2020-08-21 CO CONC2020/0010306A patent/CO2020010306A2/en unknown
- 2020-08-27 PH PH12020551343A patent/PH12020551343A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200128414A (en) | 2020-11-12 |
| CN111801100A (en) | 2020-10-20 |
| PH12020551343A1 (en) | 2021-06-21 |
| JP2021514972A (en) | 2021-06-17 |
| TW202003518A (en) | 2020-01-16 |
| RU2020131012A (en) | 2022-03-28 |
| CO2020010306A2 (en) | 2020-08-31 |
| EP3758707A1 (en) | 2021-01-06 |
| MX2020008746A (en) | 2020-09-28 |
| IL276817A (en) | 2020-10-29 |
| JP7089596B2 (en) | 2022-06-22 |
| SG11202008291XA (en) | 2020-09-29 |
| WO2019166432A1 (en) | 2019-09-06 |
| MA52412A (en) | 2021-06-02 |
| CL2020002139A1 (en) | 2021-01-04 |
| AU2019228654A1 (en) | 2020-09-03 |
| CN111801100B (en) | 2023-10-24 |
| AR114419A1 (en) | 2020-09-02 |
| CA3091950A1 (en) | 2019-09-06 |
| BR112020016509A2 (en) | 2020-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211456A1 (en) | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND ITS DERIVATIVES FOR THE TREATMENT AND PREVENTION OF LIVER CANCER | |
| PE20190329A1 (en) | FXR MODULATOR COMPOUNDS (NR1H4) | |
| PE20220597A1 (en) | PHENYLAMINOPYRIMIDINE AMIDE INHIBITORS OF AUTOPHAGY AND METHODS OF USE OF SUCH | |
| AR081058A1 (en) | DERIVATIVES OF ARILMETOXI ISOINDOLINA, COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF CANCER. | |
| PE20212247A1 (en) | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS OF THESE AND METHODS OF TREATMENT WITH THESE | |
| AR110139A1 (en) | MONO AND SPIROCYCLES COMPOUNDS CONTAINING CYCLLOBUTAN AND AZETIDINE AS INHIBITORS OF INTEGRINE AV | |
| DOP2018000187A (en) | DERIVATIVES OF PIRAZOLO [1,5-A] PIRAZIN-4-ILO | |
| MX386103B (en) | MCL-1 INHIBITORS AND METHODS OF USING THEM. | |
| AR055592A1 (en) | DERIVATIVES OF 2-AMINO-5-CYCLALKYL-HYDANTOINE AS MODULATORS AND / OR INHIBITORS OF BETA-SECRETASE (BACE) | |
| AR078163A1 (en) | USE OF AMINODIHYDROTIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | |
| AR108906A1 (en) | BIARILMETILE HETEROCICLES | |
| PE20181298A1 (en) | BIVALENT BROMODOMINIUM INHIBITORS AND USES OF THEM | |
| PE20181304A1 (en) | INDEOL N-SUBSTITUTE DERIVATIVES AS MODULATORS OF PGE2 RECEPTORS | |
| AR074021A1 (en) | FUSIONED HETEROCICLICAL COMPOUNDS AS IONIC CHANNEL MODULATORS | |
| AR088535A1 (en) | DERIVATIVES OF AMIDAS OF REPLACED AMINO ACIDS WITH N-UREA AS FORMUL RECEPTOR MODULATORS PEPTIDE RECEIVER OF TYPE 1 RECEPTOR (FPRL-1) | |
| EA201690019A1 (en) | AMINOTRIASIN DERIVATIVE AND CONTAINING ITS PHARMACEUTICAL COMPOSITION | |
| AR079205A1 (en) | MORPHOLINOTIAZOLS AS POSITIVE ALOSTERIC MODULATORS ALFA 7 | |
| AR100810A1 (en) | 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS | |
| AR104528A1 (en) | COMPOUNDS AND DERIVATIVES OF SULFONIMIDOILPURINONE FOR THE TREATMENT AND PROFILAXIS OF VIVIC INFECTIONS | |
| AR103232A1 (en) | TGFbR ANTAGONISTS | |
| PE20170684A1 (en) | OPTIONALLY CONDENSED PYRIMIDINE HETEROCICLYL DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | |
| EA201990902A1 (en) | BRUTON TYROSINKINASE INHIBITORS | |
| PE20190504A1 (en) | NMDA ESPIRO-LACTAM RECEIVER MODULATORS AND USE OF THE SAME | |
| AR076401A1 (en) | BISARIL ALQUINILAMIDAS AS NEGATIVE ALLOSTERIC MODULATORS OF THE METABOTROPIC RECEIVER OF GLUTAMATE 5 (MGLUR5) | |
| AR092288A1 (en) | EP1 RECEIVER LIGANDS |